Significant differences in access to tests and treatments for multiple myeloma between public and private systems in Latin America. Results of a Latin American survey. GELAMM (Grupo de Estudio Latino Americano de Mieloma Múltiple)

The incidence of multiple myeloma (MM) has increased in the last 20 years, particularly in middle and low-middle income countries. Access to diagnostic and prognostic tests and the availability of effective care is highly variable globally. Latin America represents 10% of the world population, distr...

Full description

Saved in:

Bibliographic Details
Published in:	Annals of hematology Vol. 99; no. 5; pp. 1025 - 1030
Main Authors:	Riva, Eloísa, Schütz, N., Peña, C., Ruiz-Argüelles, G., Hopkins, C. Rojas, Bove, V., Villano, F., Andino, L., Suárez, L., Martínez, H., Navarro, J., López-Vidal, H., Da Costa, O., Pineda, M. Rodriguez, Rubio, Y., Ramirez, J., Choque, J., Fantl, D.
Format:	Journal Article
Language:	English
Published:	Berlin/Heidelberg Springer Berlin Heidelberg 01-05-2020 Springer Nature B.V
Subjects:	Cross-Sectional Studies Health Services Accessibility Hematology Latin America - epidemiology Medical diagnosis Medicine Medicine & Public Health Multiple myeloma Multiple Myeloma - diagnosis Multiple Myeloma - epidemiology Multiple Myeloma - therapy Oncology Original Article Private Practice Public Health Practice Surveys and Questionnaires Latin America Diagnostic hematology Latin American countries Health care systems Multiple myeloma
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	The incidence of multiple myeloma (MM) has increased in the last 20 years, particularly in middle and low-middle income countries. Access to diagnostic and prognostic tests and the availability of effective care is highly variable globally. Latin America represents 10% of the world population, distributed in countries of varied size, population, and socio-economic development. In the last decade, great improvements have been made in the diagnosis and treatment of MM. Applying these advances in real life is a challenge in our region. Local data regarding MM standards of care and outcomes are limited. A survey was carried out among hematologists from 15 Latin American countries to describe access to MM diagnostic and prognostic tests and the availability of effective care options. This study provides real-world data for MM in our region, highlighting striking differences between public and private access to essential analyses and therapeutic options.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23
ISSN:	0939-5555 1432-0584
DOI:	10.1007/s00277-020-03983-x